Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma.

adult oncology anxiety disorders dermatological tumours mental health qualitative research

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
03 Mar 2022
Historique:
entrez: 4 3 2022
pubmed: 5 3 2022
medline: 28 4 2022
Statut: epublish

Résumé

Fear of cancer recurrence (FCR) is commonly reported by patients diagnosed with early-stage (0-II) melanoma and can have a significant impact on daily functioning. This study will pilot the implementation of the Melanoma Care Program, an evidence-based, psychological intervention to reduce FCR, into routine practice, using a stepped-care model. Intervention effectiveness and level of implementation will be investigated using a hybrid type I design. Between 4 weeks before and 1 week after their next dermatological appointment, patients with melanoma will be invited to complete the Fear of Cancer Recurrence Inventory Short-Form, measuring self-reported FCR severity. Using a stepped-care model, clinical cut-off points will guide the level of support offered to patients. This includes: (1) usual care, (2) Ethics approval was granted by the Sydney Local Health District-Royal Prince Alfred Zone (2020/ETH02518), protocol number: X20-0495. Results will be disseminated through peer-reviewed journals, conference presentations, social media and result summaries distributed to interested participants. TRIAL REGISTRATION DETAILS: (ACTRN12621000145808).

Identifiants

pubmed: 35241467
pii: bmjopen-2021-054337
doi: 10.1136/bmjopen-2021-054337
pmc: PMC8896053
doi:

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e054337

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: RS has received honoraria for advisory board participation from MSD, Novartis and QBiotics, and speaking honoraria from BMS. DM has received honoraria for advisory board participation from MSD, BMS and Novartis, and speaking honoraria from BMS and MSD.

Références

J Clin Oncol. 2016 Dec 20;34(36):4405-4414
pubmed: 27998215
Behav Res Ther. 2017 Nov;98:39-57
pubmed: 27865431
Qual Life Res. 2016 Feb;25(2):311-321
pubmed: 26341969
JAMA Dermatol. 2018 Jan 1;154(1):52-59
pubmed: 29188268
Front Psychol. 2021 Jun 07;12:661190
pubmed: 34163405
Implement Sci. 2017 Feb 10;12(1):15
pubmed: 28187747
J Cancer Surviv. 2015 Sep;9(3):481-91
pubmed: 25603948
BMJ. 2017 Mar 6;356:i6795
pubmed: 28264797
Support Care Cancer. 2016 Aug;24(8):3265-8
pubmed: 27169703
Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):330-57
pubmed: 22203825
BMC Psychol. 2015 Jul 11;3(1):23
pubmed: 26167282
Eur J Surg Oncol. 2013 Mar;39(3):297-303
pubmed: 23287820
Psychooncology. 2019 May;28(5):989-996
pubmed: 30825239
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
Surg Clin North Am. 2020 Feb;100(1):1-12
pubmed: 31753105
J Clin Oncol. 2019 Nov 1;37(31):2899-2915
pubmed: 31532725
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Psychooncology. 2017 Nov;26(11):1784-1791
pubmed: 28052599
BMC Cancer. 2013 Apr 23;13:201
pubmed: 23617696
J Clin Med. 2020 Sep 14;9(9):
pubmed: 32937942
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Qual Health Res. 2012 Aug;22(8):1102-13
pubmed: 22673092
BMJ Open. 2017 Apr 3;7(4):e013318
pubmed: 28373250
J Cancer Surviv. 2013 Sep;7(3):300-22
pubmed: 23475398
BMC Psychol. 2015 Sep 16;3:32
pubmed: 26376626
BMJ. 2013 Feb 05;346:e5793
pubmed: 23386361
Psychol Assess. 2013 Dec;25(4):1103-10
pubmed: 23730826
Anxiety Stress Coping. 2007 Sep;20(3):253-65
pubmed: 17999228
Psychol Rep. 2018 Jun;121(3):548-565
pubmed: 28836917
Appl Health Econ Health Policy. 2019 Oct;17(5):669-681
pubmed: 31228015
Support Care Cancer. 2016 Dec;24(12):4849-4859
pubmed: 27465047
Front Psychol. 2021 Feb 22;12:596682
pubmed: 33692719
Psychooncology. 2016 Jul;25(7):832-8
pubmed: 26489770
J Psychother Pract Res. 1999 Spring;8(2):142-54
pubmed: 10079461
J Clin Oncol. 2017 Dec 20;35(36):4066-4077
pubmed: 29095681
Br J Dermatol. 2020 Apr;182(4):860-868
pubmed: 30965384
Psychooncology. 2018 Feb;27(2):695-699
pubmed: 28370644
Support Care Cancer. 2009 Mar;17(3):241-51
pubmed: 18414902
Psychooncology. 2018 Feb;27(2):492-499
pubmed: 28755462
Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39
pubmed: 16004657

Auteurs

Jake R Thompson (JR)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia jake.thompson@melanoma.org.au.

Andrea L Smith (AL)

Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.

Serigne N Lo (SN)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia.

Nadine A Kasparian (NA)

Cincinnati Children's Center for Heart Disease and Mental Health, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Robyn Pm Saw (RP)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia.
Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Mbathio Dieng (M)

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.

Linda Seaman (L)

Consumer Representative, Sydney, New South Wales, Australia.

Linda K Martin (LK)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia.
Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.

Pascale Guitera (P)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia.
Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Donna Milne (D)

Melanoma and Skin Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Helen Schmid (H)

The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.

Anne E Cust (AE)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia.
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.

Iris Bartula (I)

Melanoma Institute Australia, University of Sydney, North Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH